awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4E
Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4E
Checkpoint and PARP inhibitors, for whom and when.
P2860
Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7d68efe7160dd1ada25d682bb60e2db0c0cfd8cf
P2860
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-